Background <p>Lung cancer remains one of the leading causes of cancer-related mortality worldwide, significantly impacting patient quality of life. Integrating Traditional Asian Medicine (TAM), such as acupuncture and herbal medicine, with standard cancer treatments may offer additional therapeutic benefits by improving efficacy and reducing adverse effects. However, the clinical evidence supporting this approach is inconsistent, necessitating a systematic evaluation.</p> Methods <p>This study protocol outlines a systematic review and meta-analysis to evaluate the effectiveness and safety of TAM as an adjunctive therapy for lung cancer patients undergoing standard treatments. Eligible studies include randomized controlled trials published in English, Korean, or Chinese up to June 2024. Data will be extracted from domestic and international databases, including PubMed, EMBASE, and KMBASE. Primary outcomes will assess tumor response using RECIST criteria, while secondary outcomes include survival rates, quality of life, and adverse effects. Statistical heterogeneity will guide the choice of fixed- or random-effects models during meta-analysis.</p> Discussion <p>This protocol aims to generate high-quality evidence supporting the integration of TAM in lung cancer care. Findings from this review may contribute to the development of clinical practice guidelines, enhancing patient outcomes and informing future research in integrative oncology.</p> Trial Registration <p>This study has been registered in PROSPERO with the registration number CRD42024523418 on March 22, 2024.</p>